Aptevo Therapeutics (APVO) News Today → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Free APVO Stock Alerts $1.16 +0.05 (+4.50%) (As of 05/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAptevo Therapeutics (NASDAQ:APVO) Stock Crosses Below 50-Day Moving Average of $3.62americanbankingnews.com - May 3 at 5:02 AMWhy Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarketmsn.com - May 2 at 7:32 AMWhy Aptevo Therapeutics Stock Is Crateringmsn.com - April 11 at 5:16 PMWhy Is Aptevo Therapeutics (APVO) Stock Down 56% Today?investorplace.com - April 11 at 8:15 AMAptevo Therapeutics Up 20% on Positive Interim Data for Tumor Drugmarketwatch.com - March 7 at 6:21 PMAlligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4finance.yahoo.com - March 7 at 1:21 PMmarketbeat.com - March 7 at 11:32 AMmarketbeat.com - March 7 at 11:10 AMmarketbeat.com - March 7 at 11:10 AMmarketbeat.com - March 7 at 10:47 AMmarketbeat.com - March 7 at 9:35 AMAptevo Therapeutics Inc (AP8N.BE)ca.finance.yahoo.com - March 6 at 4:47 PMAptevo Therapeutics enacts reverse stock split to meet Nasdaq requirementsinvesting.com - March 6 at 4:47 PMmarketbeat.com - March 6 at 6:08 AMAPVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q4 2023investorplace.com - March 5 at 2:32 PMAptevo Therapeutics Inc (AP8N.DU)finance.yahoo.com - March 5 at 2:39 AMAptevo Therapeutics down 13%, will effect 1-for-44 reverse stock splitmsn.com - March 4 at 10:17 AMPD-1 and PD-L1 Inhibitors Competitive Landscape Report 2024: Clinical Assessment of Over 200 Drugs Being Developed by More than 180 Companiesuk.finance.yahoo.com - March 1 at 1:22 PMAptevo Therapeutics Inc (APVO)investing.com - February 9 at 8:47 PMAptevo Therapeutics Stockholders Approve Reverse Splitmsn.com - February 7 at 11:14 AMAptevo Therapeutics Inc. (APVO)finance.yahoo.com - January 24 at 12:07 AMAptevo Therapeutics files to sell up to 32.03M shares of common stock for holdersmsn.com - November 22 at 6:04 PMAptevo Therapeutics GAAP EPS of -$0.50msn.com - November 14 at 9:58 AMAptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Updatefinance.yahoo.com - November 14 at 9:58 AMAptevo Therapeutics: Aptevo to Present at Bio-Europe Conferencefinanznachrichten.de - November 1 at 9:51 AMAptevo to Present at Bio-Europe Conferencefinance.yahoo.com - November 1 at 9:51 AMWith New Cash Aptevo Goes It Alone on Prostate Drug, Shares Up - Biotech Moversthestreet.com - October 21 at 3:33 PMAptevo Therapeutics Incmoney.usnews.com - September 26 at 2:49 AMAptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Updatefinance.yahoo.com - August 10 at 8:46 AMAptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offeringfinance.yahoo.com - August 4 at 11:22 PMAptevo Therapeutics (APVO) Price Target Increased by 24.14% to 18.36msn.com - August 3 at 8:34 AMWhy Aptevo Therapeutics Stock Is Getting Obliteratedbenzinga.com - August 2 at 3:37 PMWhy Is Aptevo Therapeutics (APVO) Stock Down 33% Today?investorplace.com - August 2 at 10:10 AMAptevo Therapeutics down 25% after pricing $5M offeringmsn.com - August 2 at 6:29 AMAptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offeringfinance.yahoo.com - August 2 at 1:28 AMAptevo Therapeutics: Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AMLfinanznachrichten.de - July 18 at 1:09 PMAptevo Therapeutics Stock Is Sinking Today - Here's Whybenzinga.com - July 18 at 1:09 PMAPVO - Aptevo Therapeutics Inc.ca.finance.yahoo.com - June 29 at 3:35 PMAptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Updatefinance.yahoo.com - May 11 at 10:58 AMAptevo Therapeutics Full Year 2022 Earnings: EPS Beats Expectationsfinance.yahoo.com - April 1 at 11:28 AMAptevo Therapeutics Raises $9.6 Million in Non-Dilutive Fundingfinance.yahoo.com - March 30 at 12:33 PMAptevo Therapeutics Reports 2022 Financial Results and Provides Business Updatefinance.yahoo.com - March 30 at 12:33 PMAptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumorsfinance.yahoo.com - January 9 at 12:54 PMAptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit Ratefinance.yahoo.com - December 20 at 10:02 AMShort Volatility Alert: Aptevo Therapeuticbenzinga.com - December 14 at 2:08 AM100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)finance.yahoo.com - December 12 at 7:46 AMAptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlightsfinance.yahoo.com - November 10 at 5:53 PMAlligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeuticsfinance.yahoo.com - November 9 at 8:31 AMAptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Expositionfinance.yahoo.com - November 3 at 1:59 PMAPVO Aptevo Therapeutics Inc.seekingalpha.com - October 1 at 8:39 PM Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address Incredible Opportunity to Retire FAST! (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market. Click here to get instant access to the guide APVO Media Mentions By Week APVO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APVO News Sentiment▼0.300.38▲Average Medical News Sentiment APVO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APVO Articles This Week▼20▲APVO Articles Average Week Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AMPE News ATHX News SXTC News CALA News ADTX News BLPH News EVFM News SBFM News NEPT News EVLO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APVO) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe asset beating inflation by 4xColonial MetalsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsObama’s Forever Term [exposed]Porter & CompanyPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyProtect Your Bank Account Before It’s Too LateWeiss RatingsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.